Goldman Sachs Upgrades Waters; Downgrades Agilent, Genomic Health | GenomeWeb

NEW YORK (GenomeWeb News) – Goldman Sachs today downgraded Agilent Technologies and Genomic Health, but upgraded Waters.

The changes to the three firms' ratings are part of a "recalibrating" of the investment bank's Life Science Tools portfolio in light of tighter credit in China and an "underappreciated risk" of renewed austerity as the US Fiscal Year 2014 budget and debt ceiling "come back into focus," analyst Isaac Ro said in a research report.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.